These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 32371100)
1. Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu Fulton MG; Loch MT; Rodriguez AL; Lin X; Javitch JA; Conn PJ; Niswender CM; Lindsley CW Bioorg Med Chem Lett; 2020 Jul; 30(13):127212. PubMed ID: 32371100 [TBL] [Abstract][Full Text] [Related]
2. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2. Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915 [TBL] [Abstract][Full Text] [Related]
4. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2. Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence. Dhanya RP; Sheffler DJ; Dahl R; Davis M; Lee PS; Yang L; Nickols HH; Cho HP; Smith LH; D'Souza MS; Conn PJ; Der-Avakian A; Markou A; Cosford ND J Med Chem; 2014 May; 57(10):4154-72. PubMed ID: 24735492 [TBL] [Abstract][Full Text] [Related]
6. Challenges in the Discovery and Optimization of mGlu Fulton MG; Loch MT; Cuoco CA; Rodriguez AL; Days E; Vinson PN; Kozek KA; Weaver CD; Blobaum AL; Conn PJ; Niswender CM; Lindsley CW Lett Drug Des Discov; 2019 Dec; 16(12):1387-1394. PubMed ID: 32201485 [TBL] [Abstract][Full Text] [Related]
18. Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. Layton ME; Reif AJ; Hartingh TJ; Rodzinak K; Dudkin V; Wang C; Arrington K; Kelly MJ; Garbaccio RM; O'Brien JA; Magliaro BC; Uslaner JM; Huszar SL; Fillgrove KL; Tang C; Kuo Y; Jacobson MA Bioorg Med Chem Lett; 2016 Feb; 26(4):1260-4. PubMed ID: 26810316 [TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT Poulie CBM; Liu N; Jensen AA; Bunch L J Med Chem; 2020 Sep; 63(17):9928-9949. PubMed ID: 32815361 [TBL] [Abstract][Full Text] [Related]
20. Allosteric modulators enhance agonist efficacy by increasing the residence time of a GPCR in the active state. Cao AM; Quast RB; Fatemi F; Rondard P; Pin JP; Margeat E Nat Commun; 2021 Sep; 12(1):5426. PubMed ID: 34521824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]